SEARCH

SEARCH BY CITATION

References

  • 1
    European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
  • 2
    Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
  • 3
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
  • 4
    Cellcept® Prescribing Information. Nutley, NJ, USA: Roche Laboratories Inc. Revised February 2010.
  • 5
    Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 2006: 6: 1111.
  • 6
    Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005: 80: S244.
  • 7
    Kaplan B, Meier-Kriesche HU, Minnick P et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005: 19: 551.
  • 8
    Park JM, Lake KD, Cibrik DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. Ther Drug Monit 2008: 30: 591.
  • 9
    Grinyó JM, Ekberg H, Mamelok RD et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony Pharmacokinetic Substudy. Nephrol Dial Transplant 2009: 24: 2269.
  • 10
    Gourishankar S, Houde I, Keown P et al. The CLEAR Study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010: 5: 1282.
  • 11
    Knoll GA, Macdonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
  • 12
    Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005: 19: 779.
  • 13
    Shah S, Collett D, Johnson R, Raftery M, Rudge C, Yaqoob MM. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United Kingdom. Transplantation 2008: 86: 1035.
  • 14
    Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004: 17: 609.
  • 15
    Machnicki G, Ricci JF, Brennan DC, Schnitzler MA. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics 2008: 26: 951.
  • 16
    Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
  • 17
    Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008: 86: 371.
  • 18
    Shehata M, Bhandari S, Venkat-Raman G et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int 2009: 22: 821.
  • 19
    Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
  • 20
    Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Series B Meth 1972: 34: 187.
  • 21
    Hosmer DW Jr, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley, 1999.
  • 22
    Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. New York, NY: John Wiley, 2004.
  • 23
    Poggio ED, Wang X, Weinstein DM et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006: 6: 100.
  • 24
    Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999: 21: 35.
  • 25
    Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007: 7: 1506.
  • 26
    van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney Transplantation. Transplantation 1999: 68: 261.
  • 27
    Arns W. Non-infectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007: 39: 88.
  • 28
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2009: 41: 3683.
  • 29
    Massari P, Duro-Garcia V, Girón F et al; MyPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005: 37: 916.
  • 30
    Salvadori M, Holzer H, de Mattos A et al; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
  • 31
    Budde K, Curtis J, Knoll G et al; ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004: 4: 237.
  • 32
    Chan L, Mulgaonkar S, Walker R et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.